Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.39 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.39 |
| ▸ | DHODH | Q02127 | 3/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.38 |
| ▸ | CTSA | P10619 | 1/20 | 0.38 |
| ▸ | ERN1 | O75460 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6080319 | 0.90 | CNR1 (0.46) | NOTUMMCL1LMNAHPGDCNR1 | |
| SCHEMBL6588409 | 0.90 | MCL1 (0.46) | MCL1PTGER1PTPN1DHODHMRGPRX4 | |
| SCHEMBL6080550 | 0.87 | MAPT (0.45) | MCL1LMNAHPGDPTPN1DHODH | |
| SCHEMBL6081276 | 0.86 | LMNA (0.42) | NOTUMMCL1LMNAHPGDPTPN1 | |
| SCHEMBL6080624 | 0.83 | CYP11B1 (0.48) | LMNAHPGDPTPN1 | |
| SCHEMBL6080387 | 0.81 | NOTUM (0.50) | NOTUM | |
| SCHEMBL6079995 | 0.81 | HPGD (0.44) | NOTUMLMNAHPGDERN1 | |
| SCHEMBL6080125 | 0.81 | LMNA (0.47) | NOTUMLMNAHPGDMRGPRX4 | |
| SCHEMBL6080510 | 0.81 | LMNA (0.47) | NOTUMLMNAHPGDPTGER1 | |
| SCHEMBL6594732 | 0.80 | MCL1 (0.49) | MCL1PTGER1PTPN1MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NEURO3D (FR) | 2006-08-17 | — | — | US | claimed |
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NEURO3D (FR) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NQO1, NQO2, RECQL | NOTUM 1846/4885MCL1 998/4885LMNA 2027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.